Pfizer Wins Celebrex Challenge

Law360, New York (March 20, 2007, 12:00 AM EDT) -- A New Jersey federal court has rejected a challenge by Israeli generics maker Teva Pharmaceuticals to Pfizer’s blockbuster painkiller Celebrex, Pfizer said Tuesday.

Judge John C. Lifland of the U.S. District Court for New Jersey upheld the three main U.S. patents covering Celebrex, the company's selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation, Pfizer said.

Judge John C. Lifland ruled that the patents covering the active ingredient, pharmaceutical composition and method of use for Celebrex are valid, enforceable and infringed by the generic...
To view the full article, register now.